Lantern Pharma announces collaboration with Oregon Therapeutics to advance AI-driven cancer drug development
Lantern Pharma Inc. (NASDAQ: LTRN) announced a strategic collaboration with French biotech company Oregon Therapeutics to enhance the development of XCE853, a first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate. The partnership, utilizing Lantern Pharma’s proprietary RADR AI platform, aims to identify biomarkers and gene signatures that will guide XCE853’s clinical application in treating various […]